Merck & Co (NY:MRK)

It’s fairly common knowledge that our data is being used to learn and predict human behavior, often to the benefit of the companies who aggregate and analyze this data. But can these diverse data sets...

Can Big Data Make Patient Care More Personalized And Effective?

October 28, 2022

Via TheNewswire.com

Merck Stock Price Rose as the Company Raised Its Full-Year Outlook Due to the Success of Keytruda

October 27, 2022

Merck & Co Inc (NYSE:MRK) A rise in demand for blockbuster cancer treatment Keytruda and human papillomavirus vaccination Gardasil contributed to Merck & Co Inc (NYSE: MRK) higher-than-expected sales...

Via PressReach

Topics Intellectual Property

Merck Beats Expectations for the Third Quarter as Sales of the COVID-19 Tablet Are Partially Offset by Keytruda

October 27, 2022

Merck stock was trading at $100.91 as of 09:49 AM EDT. After reporting stronger-than-anticipated financial results for the third quarter of 2022, Merck (NYSE:MRK) saw its pre-market trading price...

Via PressReach

Merck Announces Third-Quarter 2022 Financial Results

October 27, 2022

Yes, Eli Lilly and Company (NYSE: LLY) pays dividends but there is more to investing in this stock than a simple “yes” answer. The Eli Lilly dividend is safe enough but it may not be right for all...

Eli Lilly Dividend: Does Eli Lilly Pay Dividends?

October 27, 2022

Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck

October 26, 2022

European Commission Expands Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents

October 24, 2022

Merck’s PREVYMIS™ Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation

October 22, 2022

Stocks are staging a rally to end the week. But economic data next week may bring more volatility. Here are some of the most popular articles from this week

MarketBeat: Week in Review 10/17-10/21

October 22, 2022

Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments.

Topics Economy

Merck Nears Breakout Point After October Surprise Good News

October 19, 2022

Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates

Topics Stocks

October 18, 2022

Merck Recognized on Fortune’s 2022 Change the World List for Expanding Access to HPV Vaccines

October 10, 2022

Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)

October 10, 2022

Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)

October 06, 2022

U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit

September 29, 2022

Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27

September 29, 2022

Merck Animal Health Completes Minority Investment in LeeO Precision Farming

September 27, 2022

Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

September 27, 2022

Merck Animal Health to Acquire Vence

September 22, 2022

LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer

September 22, 2022

U.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit

September 22, 2022

From Merck & Co., Inc. Merck

Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection

September 20, 2022

Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children

September 16, 2022

Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

September 12, 2022

Via JCN Newswire

Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

September 12, 2022

From Seagen Inc.

Five-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)

September 11, 2022

Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

September 10, 2022

LYNPARZA® (olaparib) in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Exploratory Analyses of Two Phase 3 Trials

September 09, 2022

Merck Foundation Launches $20 Million Initiative to Advance Equity in U.S. Cancer Care

September 08, 2022

From Merck Foundation